{"analyses":[{"ciLowerLimit":"0.661","ciPctValue":"95","ciUpperLimit":"1.104","groupDescription":"P-value was obtained from 1-sided log-rank test stratified by ECOG PS score, brain metastases, and prior EGFR TKI treatment. The hazard ratio and corresponding 95% CI from the stratified Cox proportional hazards model were also presented.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1145","pValueComment":"Statistical significance: 1-sided at alpha=0.025","paramType":"Hazard Ratio (HR)","paramValue":"0.854","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.9","upperLimit":"30.5","value":"21.7"},{"groupId":"OG001","lowerLimit":"16.8","upperLimit":"26.0","value":"21.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"OS: Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who were randomized to study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization until death (up to 4.5 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}